About us
Products
Careers
Investor Relations
News
Cares
Language:
- Italiano
- English

Home » News » PHARMANUTRA GROUP LAUNCHES FOUR NEW PRODUCTS

PHARMANUTRA GROUP LAUNCHES FOUR NEW PRODUCTS

Published: 13 September 2018 09:27

<< Articolo precedente Next Article >>

Related News

(Italiano) Congresso ASH 2019: presentato...

Sorry, this entry is only available in Italian.
(Italiano) CPhI Worldwide 2019: tre giorni...

Sorry, this entry is only available in Italian.

Related Products

DiKappa2

Dikappa2 is a nutritional supplement containing Vitamin K2 and Vitamin D which promotes intestinal calcium...
Novomega

Nutritional supplement containing EPA and DHA aimed at treating alimentary deficiency or as a complement...

Pharmanutra SpA is a pharmaceutical company based in Pisa. It was founded in 2003 with the aim of developing nutraceuticals and medical devices. Pharmanutra follows rigorous standards of quality by maintaining a high attention to the raw materials used, unique and exclusive for the whole national territory.

PharmaNutra Spa | Registered office

Via Delle Lenze, 216/b

56122 Pisa

Tel. +39 050 7846500

Fax +39 050 7846524

C.F. / P.Iva / Reg. Impr. 01679440501

Codice Destinatario Fatturazione Elettronica SUBM70N

Cap.Soc. € 1.123.097,70

I.V. | REA 146259

Privacy policy
Cookie policy
General conditions
Code of ethics
Mod. 231

NEWSLETTER

Subscribe to the Pharmanutra newsletter and you will be constantly updated on all our activities.

Read Newsletter Disclosure

AWARDS

QUALITY

Ai sensi delle Nuove Linee guida del Ministero della Salute del 28/03/2013, relative alla pubblicità sanitaria concernente i dispositivi medici, dispositivi medico-diagnostici in vitro, presidi medico chirurgici e medicinali da banco, si avvisa l'utente che le informazioni ivi contenute sono esclusivamente rivolte agli operatori professionali.

© Copyright - PHARMANUTRA.IT. All Rights Reserved.

© Copyright - PHARMANUTRA.IT

All Rights Reserved.

This site is set to allow the use of all cookies in order to ensure a better navigation. If you continue to browse, you accept our cookies use. Read More